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Background: Field vaccination trials with Mycobacterium bovis BCG, an attenuated mutant of M. bovis, are ongoing
in Spain, where the Eurasian wild boar (Sus scrofa) is regarded as the main driver of animal tuberculosis (TB). The
oral baiting strategy consists in deploying vaccine baits twice each summer, in order to gain access to a high
proportion of wild boar piglets. The aim of this study was to assess the response of wild boar to re-vaccination with
BCG and to subsequent challenge with an M. bovis field strain.
Results: BCG re-vaccinated wild boar showed reductions of 75.8% in lesion score and 66.9% in culture score, as
compared to unvaccinated controls. Only one of nine vaccinated wild boar had a culture-confirmed lung infection,
as compared to seven of eight controls. Serum antibody levels were highly variable and did not differ significantly
between BCG re-vaccinated wild boar and controls. Gamma IFN levels differed significantly between BCG
re-vaccinated wild boar and controls. The mRNA levels for IL-1b, C3 and MUT were significantly higher in vaccinated
wild boar when compared to controls after vaccination and decreased after mycobacterial challenge.
Conclusions: Oral re-vaccination of wild boar with BCG yields a strong protective response against challenge with
a field strain. Moreover, re-vaccination of wild boar with BCG is not counterproductive. These findings are relevant
given that re-vaccination is likely to happen under real (field) conditions.
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Wildlife vaccination is increasingly being explored as a
tuberculosis (TB) control tool in all major wildlife reser-
voirs. An attenuated mutant of M. bovis, Mycobacterium
bovis BCG (bacille Calmette Guerin [1]), is often the
vaccine used in wildlife vaccination trials worldwide
[2-8]. In countries such as UK and the Republic of
Ireland, Eurasian badger (Meles meles) vaccination field
trials are becoming part of the TB control strategies [9].* Correspondence: christian.gortazar@uclm.es
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unless otherwise stated.Field vaccination trials are also ongoing in Spain, where
the Eurasian wild boar (Sus scrofa) is regarded as the
main driver of animal TB at the wildlife-livestock inter-
face [10-12].
In Mediterranean Spain, modeling of tuberculosis in
wild boar populations predicted that over 70% of the an-
nual cohort of wild boar piglets would be needed to be
vaccinated in order to significantly reduce the prevalence
of the disease and eventually eradicate the infection [13].
It has been demonstrated that the most efficient oral
vaccine bait deployment strategy in this area consists in
using selective piglet feeders and deploying vaccine baits
both at the start (late June/early July) and the end of
summer (late August/early September), in order to gainl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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boar piglets respectively, avoiding the hottest period
from late July to early August [14,15]. However, with this
strategy of a double delivery in summer, it would be prob-
able that some individuals actually gain access to vaccine
baits twice in a season. This possibility of some wild boar
ingesting vaccine baits in both vaccination campaigns
raises the question of the effects of re-vaccination in wild
boar. In human beings, revaccination with BCG confers
only a modest advantage over single vaccination [16,17].
Among cattle and wildlife MTC hosts, there are contro-
versial studies regarding the use of a single dose or the
need of a booster dose of the vaccine to achieve a better
vaccination protocol (Table 1). Re-vaccination has the po-
tential to be counter-productive, and such risks needed to
be assessed in wild boar as an integral part of vaccine
safety. Although adverse effects of re-vaccination or over-
dosage of BCG in wild boar were not expected, we were
interested in assessing the effects of re-vaccination with a
52 day interval imitating field conditions.
The aim of this study was to assess the response of
wild boar to re-vaccination with BCG and to subsequent
challenge with an M. bovis field strain, under experimen-
tal conditions. Based on current knowledge, we expected
a protective response similar to those recorded in previ-
ous single dose BCG vaccination experiments [2,22].
Methods
Experiment design
Seventeen 3-4-month-old wild boar piglets were bought
in a commercial farm known to be free of mycobacterial
lesions at slaughter and with a fully negative ELISA test
[23]. The animals were housed in class III bio-containment
facilities with ad libitum food and water. Wild boar piglets
were randomly assigned to treatment (BCG vaccinated
animals) or control groups (unvaccinated animals). The M.Table 1 BCG vaccination studies comparing the use of both o
and wildlife
Dose Interval Route
Red deer (Cervus
elaphus)
2 doses of 2.5×106 cfu
BCG Pasteur
8 weeks Subcutaneo
Red deer (Cervus
elaphus)
2 doses of 2×106 cfu
BCG Pasteur
6 weeks Subcutaneo
White-tailed deer
(Odocoileus virginianus)
2 doses of 107 cfu
BCG Pasteur
6 weeks Subcutaneo
Brush-tailed possum
(Trichosurus vulpecula)
12 doses of 1×108;
2 doses of 1×108 cfu
BCG Pasteur
1 Week
(12 doses);
6 weeks
(2 doses)
Intranasal a
and conjun
instillation
Cattle 2 doses of 106
CFU BCG Pasteur
6 weeks Subcutaneobovis BCG Danish reference strain (CCUG 27863) was cul-
tured on Coletsos medium (Biomerieux, France), and pre-
pared as described for previous experiments [22]. Vaccine
containing 106 cfu was administered orally in baits de-
signed for wild boar piglets [24]. For the challenge, 5 ml of
a suspension containing 105 colony forming units (cfu) of
an M. bovis field strain were administered by the oropha-
ryngeal route as described in previous experiments [2,22].
The isolate used for challenge was originally isolated from
a naturally infected wild boar and identified as M. bovis
spoligotype profile SB0339 according to the M. bovis Spoli-
gotype Database website (www.mbovis.org).
The animals were handled five times during the experi-
ment, including vaccination (T0, day 1), re-vaccination
52 days after the first vaccination (T1, day 52), challenge
74 days after re-vaccination (T2, day 126), one blood sam-
pling two months after challenge (T3, day 185) and nec-
ropsy four months after challenge (T4, day 255). Handling
procedures and sampling frequency were designed to re-
duce stress and health risks for subjects, according to
European (86/609) and Spanish laws (R.D. 223/1988, R.D.
1021/2005). The protocol was approved by the Committee
on the Ethics of Animal Experiments of the Regional
Agriculture Authority (Diputación Foral de Vizcaya, Per-
mit Number: BFA10.373 (27/19/2010)).
Sampling, pathology and microbiology
Blood samples were collected at T0-T4 time points for
RNA extraction from PBMC and serum preparation.
Animals were anesthetized by intramuscular injection of
Zoletil (Virbac, Esplugues de Llobregat, Spain) and eu-
thanized by captive bolt. At necropsy, all wild boar were
carefully inspected for the presence of macroscopic TB-
compatible lesions. Samples for culture were immedi-
ately processed and copies frozen at -80°C for mRNA
isolation. TB-compatible lesions were classified based onne single dose or repeated doses of the vaccine in cattle
Reference Effect of boosting
us [5] Two doses of vaccine were superior to one dose
producing protection against infection.
us [18] Single-dose vaccines protected against disease.
Boosting was required to protect against infection.
us [19] Pathology scores were lower in deer receiving 2
doses of M. bovis BCG compared to unvaccinated
ones or those who received a single dose.
erosol
tival
[20] The group vaccinated 12 times showed the greatest
level of protection. Revaccination after a period of
6 weeks had no beneficial and no deleterious effects
as compared to the protection induced by a single
dose of vaccine.
us [21] Significantly less protection than those vaccinated
only once. Revaccination reduced the level of
protection induced by a single vaccination.
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viously described [2]. Briefly, lymph nodes and the oro-
pharyngeal tonsils were scored as 0 (No visible lesion), 1
(1–2 small (<1 cm) caseous foci), 2 (Several small foci), 3
(Same and at least one lesion >1 cm) or 4 (Diffusely af-
fected); lung lobes were scored as 0 (No visible lesion), 1
(Few small lesions), 2 (Numerous or clustered small le-
sions with some coalescence), 3 (Densely clustered small
lesions), 4 (Same and at least one large lesion) or 5 (Two
or more large lesions). Visceral organ lesions were scored
as 0 (No visible lesion), 1 (1–2 mm foci scattered through-
out organ) or 2 (5–10 mm diameter clusters of 1–2 mm
foci or single focus >1 cm diameter). Lymphoid tissues
and samples of lung tissue were cultured for mycobacteria
and scored (total number of culture-positive samples) as
described in [22]. All isolates were spoligotyped in order
to confirm the strain [25]. Tonsil samples were flash
frozen and stored in liquid N until used for gene expres-
sion studies.
Serology and interferon tests
Serum samples were tested for anti-PPD immunoglobu-
lin G (IgG) antibodies by means of an in-house ELISA
using bovine tuberculin purified protein derivative (bovine
PPD; CZ Veterinaria SL, Porriño, Lugo, Spain) as antigen
and protein G horseradish peroxidase (Sigma-Aldrich,
Madrid, Spain) as a conjugate applying the protocol de-
scribed by Boadella et al. [23]. Serum samples were also
tested by the DPP technology developed by Chembio
Diagnostic Systems, Inc. using selected M. bovis antigens.
Briefly, the presence and intensity of either of the 2 separ-
ate test lines (T1, MPB83 antigen; T2, CFP10/ESAT-6 fu-
sion protein) were evaluated by a DPP optical reader (in
relative light units, RLU) [23]. Blood samples taken at
times 2, 3 and 4 were also used for detection of the IFN-
gamma response in presence of avian and bovine PPD, as
described previously [22].
RNA isolation and real time RT-PCR
Total RNA was extracted from wild boar PBMC and ton-
sils using TRI reagent (Sigma, Madrid, Spain) following
manufacturer’s recommendations. RNA was used for real-
time RT-PCR analysis of mRNA levels of selected genes in
individual samples. Selected genes are involved in innate
immunity (complement component 3, C3 and interleukin
1-beta, IL-1b) and methylmalonyl CoA mutase, MUT.
Real-time RT-PCR was performed with gene-specific
primers (C3, SsC3-L: acaaattgacccagcgtagg and SsC3-R:
gcacgtccttgctgtactga; IL-1b, SsIL1beta-L: ccaaagagggacatg
gagaa and SsIL1beta-R: ttatatcttggcggcctttg; MUT, Ss
MUT-L: gtttgccaacggtgaaaagt and SsMUT-R: aatgagctt
caaggcagcat) using the One-Step RT-PCR Kit with SYBR
Green and the CFX thermal cycler (Bio-Rad, Hercules,
CA, USA) following manufacturer’s recommendations.Control reactions were performed using the same proce-
dures, but without RT to monitor DNA contamination in
the RNA preparations and without RNA added to monitor
contamination of the PCR reaction. A dissociation curve
was run at the end of RT-PCR reaction to ensure that only
one amplicon was formed and that the amplicon dena-
tured consistently at the same temperature range for every
sample [26]. The mRNA values were normalized against S.
scrofa cyclophilin (SsCyclophilin-L: agcactggggagaaaggatt
and SsCyclophilin-R: cttggcagtgcaaatgaaaa), β-actin (Ss-
BactinF: ggacctgaccgactacctca and Ss-BactinR: ggcagctcg-
tagctcttcat) and GAPHD (Ss-GAPHDF: gtcggttgtggatctg
acct and Ss-GAPHDR: agcttgacgaagtggtcgtt) using the
genNorm ddCT method [27].Results
No clinical signs such as wasting or cough were recorded
during the experiment. Figure 1 presents the pathology
scores and total culture scores. BCG re-vaccinated wild
boar showed reductions of 75.8% and 66.9%, respectively,
as compared to controls (U tests; Z > 3.2, p < 0.01). Two
BCG re-vaccinated wild boar had no positive culture. The
mean (±SE) thorax culture scores were 0.22 (±0.3) for
vaccinated and 2.25 (±0.3) for control wild boar (90.2%
reduction; U test; Z = 3.1, p < 0.01). Only one of nine
vaccinated wild boar had a culture-confirmed lung in-
fection, as compared to seven of eight controls (Fisher’s
test; p = 0.003).
Serum antibody levels were highly variable and did not
differ significantly between BCG re-vaccinated wild boar
and controls (ANOVA; Treatment effect F1, 45 < 2.71, p >
0.05). Gamma IFN levels differed significantly between
BCG re-vaccinated wild boar and controls (ANOVA;
Treatment effect F1, 39 = 6.08, p < 0.05). The gamma IFN
response to bPPD was undetectable at T2. A peak was re-
corded at T3 both in BCG re-vaccinated wild boar (mean
OD± SE 6.9 ± 1.7) and in controls (11.4 ± 1.8), slightly de-
clining in both groups thereafter (Figure 2).
The mRNA levels for IL-1b, C3 and MUT were signifi-
cantly higher in vaccinated wild boar when compared to
controls at T2 and decreased after mycobacterial chal-
lenge (Figure 3A). Only IL-1b mRNA levels remained
higher in vaccinated animals when compared to controls
until the end of the experiments (Figure 3A). In tonsils,
only MUT mRNA levels were significantly higher in vac-
cinated than in control animals at the end of the experi-
ment (Figure 3B).Discussion
This experiment confirmed that oral BCG re-vaccination
of wild boar induces a strong protective response against
challenge with an M. bovis field strain. This response in-
cludes lower lesion and culture scores; lower gamma
Figure 1 Wild boar TB lesion scores (left) and culture scores (right) at necropsy. The solid lines show the median values.
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in vaccinated wild boar.
The main difference between this experiment and the
previous vaccine and challenge trials in wild boar was
re-vaccination. Although no single vaccination controls
were included, the protective response recorded after re-
vaccination (76% lesion score, 67% culture score), was
higher than those recorded in two previous single dose
BCG vaccination experiments, i.e. 56% reduction inT
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Figure 2 Mean optical density (OD) readings of the gamma interferon
wild boar. Vertical bars represent 95% confidence intervals.lesion score, 50% in culture score [2]; 52% reduction in
lesion score, 9% in culture score [22]. This animal ex-
periment was run along with another one testing a new,
heat-inactivated vaccine, and the number of available ex-
perimental wild boar and the available housing space did
not allow including a single-vaccination BCG group.
Serum antibody and gamma IFN responses were essen-
tially similar to those recorded in these single vaccin-
ation experiments. These levels of protection were betterime
T3 T4
ELISA in BCG re-vaccinated (solid line) and control (dashed line)
Figure 3 Gene expression in response to BCG vaccination in wild boar. The mRNA levels of selected genes were analyzed by real-time
RT-PCR in (A) PBMC of vaccinated and control wild boar collected at T0 (before vaccination), T2 (before challenge) and T4 (at necropsy) or
(B) tonsils at T4. The mRNA levels were normalized against S. scrofa cyclophilin, β-actin and GAPHD and normalized Ct values were represented
as Ave + S.D. in arbitrary units and compared between groups by Student´s t-test with unequal variance (*P≤ 0.05).
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African buffaloes (Syncerus caffer), in which revaccination
gave not differences in the protection for vaccinated ani-
mals compared to unvaccinated animals [4]. In ferrets
(Mustela furo), two doses of 5×108 cfu of BCG-Pasteur
given orally in a 4 week interval produced a significant re-
duction in pathology after oral challenge with virulent M.
bovis, decreasing the mean bacterial count for retrophar-
yngeal LN tissue of culture- positive vaccinated animals to
70% [7].
It is known that factors such as the variation of the
period between the administration of the two doses of
the vaccine could affect the protective efficacy of the
vaccination. For example, the reduction of this period
from 8 to 4 weeks in vaccinated red deer did not affect
the protection induced by the vaccine, whereas increasing
this period to 43 weeks largely ablated protection [28]. In
our study, wild boar vaccination took place 52 days after
the first vaccination (between 7-8 weeks), which imitates
field conditions.
Another important factor that could affect the protec-
tion of the vaccine is the dose. Low and medium booster
doses (104-107 cfu; 6-8 weeks interval) of BCG-Pasteur
produced significant protection against infection and
disease in vaccinated red deer, but higher booster doses
(5×108cfu) provided protection against disease but not
against infection [5,18]. In our case, a dose of 106 cfu
was used, again imitating field protocols.
Molecular characterization of host-pathogen interactions
identified wild boar genes such as MUT, C3 and other in-
nate and adaptive immune response genes involved inresistance to mycobacterial infection [29-33]. As in previ-
ous experiments, C3 and MUT mRNA levels rose after
vaccination and decreased after challenge [22]. The up-
regulation of genes encoding pro-inflammatory cytokines
such as pro-IL-1b probably stimulates the production of
C3 which may contribute to the protective response to
BCG vaccination in wild boar.Conclusions
Oral re-vaccination of wild boar with BCG yields a strong
protective response against challenge with a field strain.
One important conclusion of this study is that re-
vaccination of wild boar with BCG is not counterproduct-
ive as suggested for cattle [34]. This finding is relevant
given that wild boar TB is increasingly reported [35,36]
and that re-vaccination is likely to happen in the ongoing
field vaccination trials.
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